{"filing":{"accession_number":"0001816590-26-000047","cik":"0001816590","ticker":"CMPS","company_name":"COMPASS Pathways plc","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"cmps-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm"},"events":[{"id":16300,"run_id":14550,"accession_number":"0001816590-26-000047","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"COMPASS Pathways announced positive 26-week Phase 3 trial results (COMP006 Part B) for COMP360 psilocybin in treatment-resistant depression, demonstrating rapid onset and durable efficacy with a favorable safety profile. The company is pursuing a rolling NDA submission and has received an FDA National Priority Voucher, with commercial launch anticipated for end of 2026 or H1 2027.","company_name":"COMPASS Pathways plc","ticker":"CMPS","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14358,"accession_number":"0001816590-26-000047","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Item 7.01 disclosure furnishes an investor presentation regarding Phase 3 clinical trial data for COMP360 psilocybin in treatment-resistant depression (TRD). The presentation highlights positive trial results (COMP005 and COMP006), rolling NDA submission underway, FDA National Priority Voucher award, and commercial launch readiness for end of 2026/H1 2027. While the clinical data and regulatory progress are material to investors assessing the company's pipeline and commercialization prospects, this disclosure does not fit neatly into standard event categories—it is neither a formal earnings release, a regulatory approval, nor a discrete M\u0026A or capital event. The domain is clearly operational/clinical-stage development, but the specific event type (clinical data presentation and regulatory milestone update) does not match a named taxonomy category, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:08:25.512594+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14359,"accession_number":"0001816590-26-000047","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"COMPASS Pathways announced positive 26-week Phase 3 trial results (COMP006 Part B) for COMP360 psilocybin in treatment-resistant depression, demonstrating rapid onset and durable efficacy through 6 months with a favorable safety profile. While this is a clinical milestone with significant regulatory and commercial implications (rolling NDA submission underway, anticipated launch H1 2027), it does not fit the earnings_release category (no financial results disclosed) nor any other specific event type. This is a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:08:25.512594+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14358,"accession_number":"0001816590-26-000047","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Item 7.01 disclosure furnishes an investor presentation regarding Phase 3 clinical trial data for COMP360 psilocybin in treatment-resistant depression (TRD). The presentation highlights positive trial results (COMP005 and COMP006), rolling NDA submission underway, FDA National Priority Voucher award, and commercial launch readiness for end of 2026/H1 2027. While the clinical data and regulatory progress are material to investors assessing the company's pipeline and commercialization prospects, this disclosure does not fit neatly into standard event categories—it is neither a formal earnings release, a regulatory approval, nor a discrete M\u0026A or capital event. The domain is clearly operational/clinical-stage development, but the specific event type (clinical data presentation and regulatory milestone update) does not match a named taxonomy category, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:08:25.512594+00:00","company_name":"COMPASS Pathways plc","ticker":"CMPS","filing_date":"2026-07-07"},{"id":14359,"accession_number":"0001816590-26-000047","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"COMPASS Pathways announced positive 26-week Phase 3 trial results (COMP006 Part B) for COMP360 psilocybin in treatment-resistant depression, demonstrating rapid onset and durable efficacy through 6 months with a favorable safety profile. While this is a clinical milestone with significant regulatory and commercial implications (rolling NDA submission underway, anticipated launch H1 2027), it does not fit the earnings_release category (no financial results disclosed) nor any other specific event type. This is a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:08:25.512594+00:00","company_name":"COMPASS Pathways plc","ticker":"CMPS","filing_date":"2026-07-07"}]}